Discontinued — last reported Q4 '21
Year-over-year, this metric declined by 34.6%, from $535.00M to $350.00M. Over 5 years (FY 2021 to FY 2026), Short-Term Borrowings shows a downward trend with a -100.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
High levels may indicate a reliance on short-term credit markets for operational cash flow, which can increase liquidity risk.
Short-term borrowings consist of debt obligations that are due within one year, excluding the current portion of long-te...
Varies by industry; pharmaceutical firms often maintain access to short-term credit for operational flexibility.
short_term_borrowings| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.00M | $2.00M | $2.00M | $3.00M | $2.00M | $2.00M | $2.00M | $2.00M | $582.00M | $2.03B | $1.60B | $2.20B | $2.10B | $1.18B | $515.00M | $535.00M | $985.00M | $725.00M | $0.00 | $350.00M |
| QoQ Change | — | -33.3% | +0.0% | +50.0% | -33.3% | +0.0% | +0.0% | +0.0% | >999% | +249.3% | -21.2% | +37.5% | -4.6% | -44.0% | -56.2% | +3.9% | +84.1% | -26.4% | -100.0% | — |
| YoY Change | — | — | — | — | -33.3% | +0.0% | +0.0% | -33.3% | >999% | >999% | >999% | >999% | +261.2% | -42.1% | -67.9% | -75.7% | -53.1% | -38.4% | -100.0% | -34.6% |